Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial

Doaa El Amrousy, Dalia El-Afify, Abdallah Elsawy, Mai Elsheikh, Amr Donia, Mohammed Nassar, Doaa El Amrousy, Dalia El-Afify, Abdallah Elsawy, Mai Elsheikh, Amr Donia, Mohammed Nassar

Abstract

Background: Iron-deficiency anemia (IDA) is common in children with inflammatory bowel disease (IBD); however, oral iron supplements are commonly associated with poor compliance due to gastrointestinal side effects. We compared the effect of lactoferrin versus oral ferrous sulfate for the treatment of IDA in children with IBD.

Methods: Ninety-two IBD children with IDA were included but only 80 children completed the study and they were randomized into two groups: ferrous sulfate group (n = 40) who received ferrous sulfate 6 mg/kg/day for 3 months and lactoferrin group (n = 40) who received lactoferrin 100 mg/day for 3 months. Complete blood count, serum iron, total iron-binding capacity (TIBC), transferrin saturation (TS), serum ferritin, interleukin-6 (IL-6), and hepcidin 25 were measured before and after the treatment.

Results: Hemoglobin (Hb), mean corpuscular volume, serum iron, TS, and serum ferritin significantly increased, while TIBC decreased significantly after the administration of either ferrous sulfate or lactoferrin compared to their baseline data. In addition, lactoferrin significantly increased Hb, serum iron, TS, and serum ferritin compared to ferrous sulfate. Moreover, lactoferrin significantly decreased IL-6 and hepcidin levels.

Conclusion: Lactoferrin is a promising effective treatment with fewer side effects than oral elemental iron in children with IBD and IDA.

Clinical trial registration: The study was registered at www.pactr.org (PACTR202002763901803).

Impact: Iron-deficiency anemia (IDA) in children with inflammatory bowel disease (IBD) is treated with oral iron therapy; however, oral iron supplements are commonly associated with poor compliance due to gastrointestinal side effects. To the best of our knowledge, our study was the first in pediatrics that compared the effect of lactoferrin versus oral ferrous sulfate as an iron supplement for the treatment of IDA in children with IBD. We found that lactoferrin is a promising effective treatment with fewer side effects than oral elemental iron in children with IBD and IDA.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flow diagram of the study showing details of enrollment, allocation, follow up, and analysis of the patients.

References

    1. Carvalho FSG, de Medeiros IA, Antunes H. Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease. Scand. J. Gastroenterol. 2017;52:1099–1103. doi: 10.1080/00365521.2017.1342137.
    1. Lopes AI, et al. Portuguese consensus on diagnosis, treatment, and management of anemia in pediatric inflammatory bowel disease. GE Port. J. Gastroenterol. 2020;27:244–254. doi: 10.1159/000505071.
    1. Aljomah G, et al. Anemia in pediatric inflammatory bowel disease. JPGN. 2018;67:351–355.
    1. Mattiello V, et al. Diagnosis and management of iron deficiency in children with or without anemia: consensus recommendations of the SPOG Pediatric Hematology Working Group. Eur. J. Pediatr. 2020;179:527–545. doi: 10.1007/s00431-020-03597-5.
    1. Kaitha S, Bashir M, Ali T. Iron deficiency anemia in inflammatory bowel disease. World J. Gastrointest. Pathophysiol. 2015;6:62–72. doi: 10.4291/wjgp.v6.i3.62.
    1. Baker HM, Baker EN. A structural perspective on lactoferrin function. Biochem. Cell Biol. 2012;90:320–328. doi: 10.1139/o11-071.
    1. Chen K, et al. Dose effect of bovine lactoferrin fortification on iron metabolism of anemic infants. J. Nutr. Sci. Vitaminol. (Tokyo) 2020;66:24–31. doi: 10.3177/jnsv.66.24.
    1. Lepanto MS, et al. Efficacy of lactoferrin oral administration in the treatment of anemia and anemia of inflammation in pregnant and non-pregnant women: an interventional study. Front. Immunol. 2019;9:2123. doi: 10.3389/fimmu.2018.02123.
    1. Ramakrishnan T, Sivaraman M, Dutta T, Ramasamy DK. A comparative study to evaluate the efficacy of oral lactoferrin fortified bovine colostrum with oral iron in the treatment of iron deficiency anemia. Int. J. Med. Public Health. 2018;8:65–70. doi: 10.5530/ijmedph.2018.2.15.
    1. Wronowski M, et al. Bovine lactoferrin in the prevention of antibiotic-associated diarrhea in children: a randomized clinical trial. Front Pediatr. 2021;9:675606. doi: 10.3389/fped.2021.675606.
    1. Manzoni P, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. 2009;302:1421–1428. doi: 10.1001/jama.2009.1403.
    1. Levine A, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. JPEG. 2014;58:795–806.
    1. Dignass AU, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J. Crohns Colitis. 2015;9:211–222. doi: 10.1093/ecco-jcc/jju009.
    1. Hyams J, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J. Pediatr. Gastroenterol. Nutr. 2005;41:416–421. doi: 10.1097/01.mpg.0000183350.46795.42.
    1. Turner D, Hyams JV, Markowitz J. Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI) Inflamm. Bowel Dis. 2009;15:1218–1223. doi: 10.1002/ibd.20867.
    1. Gasche C, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm. Bowel Dis. 2007;13:1545–1553. doi: 10.1002/ibd.20285.
    1. Puyuelo G, Alfambra E, García-Erce JA, Gomollon F. Iron treatment may be difficult in inflammatory diseases: inflammatory bowel disease as a paradigm. Nutrients. 2018;10:1959. doi: 10.3390/nu10121959.
    1. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharm. Ther. 2001;15:1989–1999. doi: 10.1046/j.1365-2036.2001.01113.x.
    1. Paesano R, et al. Lactoferrin efficacy versus ferrous sulfate in curing iron deficiency and iron deficiency anemia in pregnant women. Biometals. 2010;23:411–417. doi: 10.1007/s10534-010-9335-z.
    1. Suzuki YA, Lonnerdal B. Characterization of mammalian receptors for lactoferrin. Biochem Cell Biol. 2002;80:75–80. doi: 10.1139/o01-228.
    1. Karaskova E, et al. Changes in serum hepcidin levels in children with inflammatory bowel disease during anti-inflammatory treatment. J. Paediatrics Child Health. 2020;56:276–282. doi: 10.1111/jpc.14593.
    1. Langer AL, Ginzburg YZ. Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation. Hemodial. Int. 2017;21:S37–S46. doi: 10.1111/hdi.12543.
    1. Legrand D. Lactoferrin a key molecule in immune and inflammatory processes. Biochem Cell Biol. 2012;90:252–268. doi: 10.1139/o11-056.
    1. Jimenez K, Kulnigg-Dabsch S, Gasche C. Management of iron deficiency anemia. Gastroenterol. Hepatol. 2015;11:241–250.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi